These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 29469175)

  • 1. Presence of autoimmune disease affects not only risk but also survival in patients with B-cell non-Hodgkin lymphoma.
    Kleinstern G; Averbuch M; Abu Seir R; Perlman R; Ben Yehuda D; Paltiel O
    Hematol Oncol; 2018 Apr; 36(2):457-462. PubMed ID: 29469175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.
    Torka P; Patel P; Tan W; Wilding G; Bhat SA; Czuczman MS; Lee KP; Deeb G; Neppalli V; Mavis C; Wallace P; Hernandez-Ilizaliturri FJ
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e51-e60. PubMed ID: 29233743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases.
    Boyle T; Connors JM; Gascoyne RD; Berry BR; Sehn LH; Bashash M; Spinelli JJ
    Br J Haematol; 2017 Aug; 178(3):442-447. PubMed ID: 28466570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
    Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Srour SA; Li S; Popat UR; Qazilbash MH; Lozano-Cerrada S; Maadani F; Alousi A; Kebriaei P; Anderlini P; Nieto Y; Jones R; Shpall E; Champlin RE; Hosing C
    Br J Haematol; 2017 Aug; 178(4):561-570. PubMed ID: 28485023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes.
    Simard JF; Baecklund F; Chang ET; Baecklund E; Hjalgrim H; -Olov Adami H; Glimelius B; Smedby KE
    Int J Cancer; 2013 Jun; 132(11):2659-66. PubMed ID: 23160780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents.
    Carrier P; Jaccard A; Jacques J; Tabouret T; Debette-Gratien M; Abraham J; Mesturoux L; Marquet P; Alain S; Sautereau D; Essig M; Loustaud-Ratti V
    Liver Int; 2015 Oct; 35(10):2222-7. PubMed ID: 26104059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
    Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
    Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma.
    Byrd KP; Vontela NR; McCullar B; Martin MG
    Anticancer Res; 2017 Dec; 37(12):6839-6843. PubMed ID: 29187463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma.
    Barta SK; Samuel MS; Xue X; Wang D; Lee JY; Mounier N; Ribera JM; Spina M; Tirelli U; Weiss R; Galicier L; Boue F; Little RF; Dunleavy K; Wilson WH; Wyen C; Remick SC; Kaplan LD; Ratner L; Noy A; Sparano JA
    Ann Oncol; 2015 May; 26(5):958-966. PubMed ID: 25632071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
    Hwang HS; Yoon DH; Suh C; Huh J
    Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
    Panizo C; Rodríguez AJ; Gutiérrez G; Díaz FJ; González-Barca E; de Oña R; Grande C; Sancho JM; García-Álvarez MF; Sánchez-González B; Peñalver FJ; Cannata J; Espeso M; Requena MJ; Gardella S; Durán S; González AP; Alfonso A; Caballero MD;
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):398-403. PubMed ID: 25843416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnic variation in medical and lifestyle risk factors for B cell non-Hodgkin lymphoma: A case-control study among Israelis and Palestinians.
    Kleinstern G; Abu Seir R; Perlman R; Khatib A; Abdeen Z; Elyan H; Nirel R; Amir G; Ramlawi A; Sabatin F; Boffetta P; Dann EJ; Kedmi M; Ellis M; Nagler A; Ben Yehuda D; Paltiel O
    PLoS One; 2017; 12(2):e0171709. PubMed ID: 28196110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
    Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
    Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abundant expression of BMI1 in follicular lymphoma is associated with reduced overall survival.
    AlJohani N; Choi SJ; Day AG; Alhejaily A; Virk S; Baetz T; LeBrun DP
    Leuk Lymphoma; 2018 Sep; 59(9):2211-2219. PubMed ID: 29251058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.